On July 1st local time, biopharmaceutical company Radionetics announced a strategic partnership with Eli Lilly and Co to advance Radionetics' proprietary GPCR-targeted small molecule radiopharmaceuticals. According to the terms of the agreement, Radionetics receives a prepayment of US$140 million in cash. Eli Lilly and Co obtains exclusive rights to acquire Radionetics for US$1 billion at the end of the exercise period.
礼来与Radionetics达成战略合作
Eli Lilly and Co reached a strategic partnership with Radionetics.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.